Presidio raises $27 million as HCV candidate nears clinic
This article was originally published in Scrip
Executive Summary
Presidio Pharmaceuticals has closed a third round of financing raising $27 million. It said the funds raised will be used to advance its hepatitis C virus (HCV) NS5A candidate through clinical studies, and to support other programmes in the pipeline.